论文部分内容阅读
近十年的临床试验证明,阿斯匹林是一种有效的抗血检形成药物,它抑制环氧化酶,该酶在血小板内产生血小板凝聚剂——血栓素A_2(TXA_2);而在血管壁细胞内环氧化酶可产生一种抗血小板凝聚剂——前列环素(PGI_2)。因此,阿斯匹林既有强的抗血栓形成作用又有强的形成血栓作用。小剂量的阿斯匹林(325mg或以下)对血小板和血管壁细胞内的环氧化酶起着抑制作用,但对TXA_2合成的抑制作用比对PGI_2合成的抑制作用大且持续时间也较长。
Nearly a decade of clinical trials have shown that aspirin is an effective anti-sera drug that inhibits cyclo-oxygenase, which produces platelet-aggregating agent, thromboxane A 2 (TXA 2) Intracellular cyclooxygenase in the vascular wall produces PGI 2, an antiplatelet coagulant. Therefore, aspirin both strong antithrombotic effect and strong thrombosis. Low doses of aspirin (325 mg or less) have an inhibitory effect on cyclooxygenase in platelets and vascular wall cells, but have a greater inhibitory effect on TXA 2 synthesis than PGI 2 synthesis and have a longer duration .